Home » Topics » Ocular, BioWorld Science

Ocular, BioWorld Science
RSS

InSite Vision brings its once-daily glaucoma treatment to clinical trials

Dec. 8, 1997

Alcon compounds with dual antioxidant/cysteine prodrug properties

Dec. 8, 1997

Spotlight on carbonic anhydrase inhibitors for glaucoma

Nov. 25, 1997

KeraVision Ring evaluated in extended phase III trial

Nov. 21, 1997

Promising phase III results reported for KeraVision ring

Nov. 4, 1997

German launch for Xalatan

Oct. 23, 1997

Patient recruitment for verteporfin phase III trials exceeds goals

Sep. 30, 1997

Lotemax deemed approvable by FDA

Sep. 26, 1997

Angiogenesis inhibitors described by Janssen

Sep. 25, 1997

AEterna initiates phase I trial in AMD

Sep. 24, 1997

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 19, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 19, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...